体外生命支持后直接植入左心室辅助装置的中期结局预测因素
该单中心回顾性研究分析了2012年至2018年间100例在体外生命支持(ECLS)后直接植入长期左心室辅助装置(LVAD)的成年患者,旨在建立预测中期结局的算法。结果显示30天、1年和2年生存率分别为62.0%、43.0%和37.1%,并识别出胆红素升高、C反应蛋白升高、ECLS持续时间>7天、BMI>30 kg/m2和女性性别是1年死亡率的预测因素,据此构建了列线图。
要点
- ECLS后直接植入LVAD的患者1年生存率仅43.0%,中期预后较差。
- ECLS持续时间>7天、高胆红素、高CRP、肥胖和女性性别增加1年死亡风险。
- 基于上述因素构建的列线图可用于估算LVAD植入后1年死亡率。
核心结论
- 对于经ECLS稳定后的心源性休克患者,植入LVAD仍可进行但死亡率升高,肝功能障碍、炎症状态和肥胖增加中期死亡风险。
研究设计与样本
- 单中心回顾性分析,2012年1月至2018年1月共714例成人接受ECLS,其中100例后续接受长期LVAD支持。
主要发现
- LVAD植入后30天、1年和2年生存率分别为62.0%(95%CI 53.2-72.3)、43.0%(95%CI 34.3-53.9)和37.1%(95%CI 28.2-48.7%)。
- 惩罚多变量logistic回归显示1年死亡率的预测因素包括:胆红素每升高1 mg/dl(OR 1.41,95%CI 1.12-1.77)、C反应蛋白每升高1 mg/dl(OR 1.11,95%CI 1.05-1.19)、ECLS持续时间>7天(OR 4.90,95%CI 1.66-14.41)、BMI>30 kg/m2(OR 1.41,95%CI 1.05-8.52)和女性性别(OR 3.06,95%CI 1.02-9.23)。
- 基于上述数据创建了估算LVAD植入后1年死亡率的列线图。
临床怎么用
- 对于ECLS后考虑植入长期LVAD的患者,应评估胆红素、CRP、ECLS持续时间、BMI和性别,以识别中期死亡高风险者。
- 列线图可用于辅助决策,但需结合临床综合判断。
局限性
- 单中心回顾性研究,样本量有限(100例),结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Extracorporeal life support (ECLS) can be applied as a bridge to diagnosis and decision-making for further treatment with long-term left ventricular assist devices (LVADs). METHODS: From January 2012 to January 2018, 714 adult patients were treated with ECLS in our institution. During the same period, 618 patients received an LVAD for long-term support. Of them, 100 patients were further supported with a long-term LVAD. We retrospectively analysed the datasets of these 100 consecutive patients with the goal of developing an algorithm to predict outcomes for a rational use of long-term ventricular assist device therapy in this setting. RESULTS: The mean age of the 100 patients was 54.1 ± 11.6 years, and 72 were men. Twenty-nine patients had a BMI of >30 kg/m2. In 33 patients, a temporary right ventricular assist device was necessary postoperatively. The 30-day, 1-year and 2-year survival after ventricular assist device implantation was 62.0% [95% confidence interval (CI) 53.2-72.3], 43.0% (95% CI 34.3-53.9) and 37.1% (95% CI 28.2-48.7%), respectively. Penalized multivariable logistic regression analysis showed following predictors for 1-year mortality: bilirubin increase per mg/dl [odds ratio (OR) 1.41, 95% CI 1.12-1.77], C-reactive protein increase per mg/dl (OR 1.11, 95% CI 1.05-1.19), ECLS duration >7 days (OR 4.90, 95% CI 1.66-14.41), BMI >30 kg/m2 (OR 1.41, 95% CI 1.05-8.52) and female gender (OR 3.06, 95% CI 1.02-9.23). On the basis of these data, a nomogram to estimate 1-year mortality after LVAD implantation was created. CONCLUSIONS: After stabilization of patients experiencing cardiogenic shock using ECLS, LVAD implantation can be performed with elevated mortality in an otherwise futile situation. Liver dysfunction, inflammatory status and obesity increase the risk for mid-term mortality.
引用
- Tsyganenko D, Gromann TW, Schoenrath F, et al. Predictors of mid-term outcomes in patients undergoing implantation of a ventricular assist device directly after extracorporeal life support. Eur J Cardiothorac Surg. 2019. PMID: 30445489. doi:10.1093/ejcts/ezy351
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。